To Demonstrate the Non-inferiority of Eyestil Protection® Compared to Vismed® in Terms of Clinical Performance
A Prospective Multicenter, Comparative, Randomized, Single-blind, Non-inferiority Study of Eyestil Protection® Unidose Versus Vismed® Unidose in Patients With Moderate to Severe Dry Eye Syndrome
Sponsor: SIFI SpA
Terminated
Slow enrolment process and COVID situation worsened the situation. SIFI has developed a new product with probably a better performance. SIFI changed its marketing strategy and decided that Eyestil® Protection will be not marketed anymore
Other Dry Eye Syndrome trials with similar outcome
A NA clinical study on Dry Eye Syndrome, this trial is terminated or withdrawn. The trial is conducted by SIFI SpA and has accumulated 9 data snapshots since 2019. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Terminated NA
-
Jul 2024 — Sep 2024 [monthly]
Terminated NA
-
Jun 2022 — Jul 2024 [monthly]
Terminated NA
Status: Suspended → Terminated
-
Dec 2021 — Jun 2022 [monthly]
Suspended NA
-
Apr 2021 — Dec 2021 [monthly]
Suspended NA
Status: Recruiting → Suspended
▶ Show 4 earlier versions
-
Jan 2021 — Apr 2021 [monthly]
Recruiting NA
-
Jun 2020 — Jan 2021 [monthly]
Recruiting NA
-
Dec 2019 — Jun 2020 [monthly]
Recruiting NA
Status: Not Yet Recruiting → Recruiting
-
Feb 2019 — Dec 2019 [monthly]
Not Yet Recruiting NA
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- SIFI SpA
For direct contact, visit the study record on ClinicalTrials.gov .